NDAORALTABLET
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
4/8 — Partial
LOPRESSOR (metoprolol tartrate) by Rubicon Biotechnology is 12. First approved in 2025.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lopressor (metoprolol tartrate) is a beta-1 selective adrenergic receptor blocking agent used to treat hypertension, angina pectoris, and acute myocardial infarction. It works by slowing heart rate and decreasing AV nodal conduction, reducing cardiac workload and blood pressure. The drug demonstrates cardioselective properties at therapeutic doses, with reduced impact on bronchial and vascular smooth muscle compared to nonselective beta-blockers.
LAUNCH
As a newly launched product, Lopressor presents growth opportunity with team expansion expected across sales, marketing, and medical affairs functions.
Mechanism of Action
12.1 Mechanism of Action Metoprolol is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular…
Worked on LOPRESSOR at Rubicon Biotechnology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.